CHCI vs. BCRX

Last updated Apr 1, 2026

Compare and contrast key facts about Comstock Holding Companies, Inc. (CHCI) and BioCryst Pharmaceuticals, Inc. (BCRX).

Performance

CHCI vs. BCRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Comstock Holding Companies, Inc. (CHCI) and BioCryst Pharmaceuticals, Inc. (BCRX). The values are adjusted to include any dividend payments, if applicable.

CHCI vs. BCRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CHCI Comstock Holding Companies, Inc.	62.99%	43.81%	82.32%	4.28%	-12.37%	53.00%	62.02%	16.46%	-1.18%	-5.56%
BCRX BioCryst Pharmaceuticals, Inc.	22.05%	3.72%	25.54%	-47.82%	-17.11%	85.91%	115.94%	-57.25%	64.36%	-22.43%

Fundamentals

EPS CHCI : $1.33 BCRX : $1.20
PE Ratio CHCI : 14.26 BCRX : 7.93
PS Ratio CHCI : 3.55 BCRX : 2.39
Total Revenue (TTM) CHCI : $55.84M BCRX : $874.84M
Gross Profit (TTM) CHCI : $11.93M BCRX : $855.43M
EBITDA (TTM) CHCI : $10.21M BCRX : $345.49M

Returns By Period

In the year-to-date period, CHCI achieves a 62.99% return, which is significantly higher than BCRX's 22.05% return. Over the past 10 years, CHCI has outperformed BCRX with an annualized return of 26.89%, while BCRX has yielded a comparatively lower 12.90% annualized return.

CHCI

• 1D: 6.46%
• 1M: 62.30%
• YTD: 62.99%
• 6M: 35.19%
• 1Y: 119.72%
• 3Y*: 55.16%
• 5Y*: 26.97%
• 10Y*: 26.89%

BCRX

• 1D: 0.74%
• 1M: 8.80%
• YTD: 22.05%
• 6M: 25.43%
• 1Y: 26.93%
• 3Y*: 4.51%
• 5Y*: -0.88%
• 10Y*: 12.90%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CHCI vs. BCRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CHCI

CHCI Risk / Return Rank: 82
CHCI Sharpe Ratio Rank: 87
CHCI Sortino Ratio Rank: 85
CHCI Omega Ratio Rank: 82
CHCI Calmar Ratio Rank: 79
CHCI Martin Ratio Rank: 73

BCRX

BCRX Risk / Return Rank: 57
BCRX Sharpe Ratio Rank: 61
BCRX Sortino Ratio Rank: 63
BCRX Omega Ratio Rank: 58
BCRX Calmar Ratio Rank: 53
BCRX Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CHCI vs. BCRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Comstock Holding Companies, Inc. (CHCI) and BioCryst Pharmaceuticals, Inc. (BCRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CHCI	BCRX	Difference
Sharpe ratio Return per unit of total volatility	1.72	0.53	+1.18
Sortino ratio Return per unit of downside risk	2.43	1.29	+1.14
Omega ratio Gain probability vs. loss probability	1.31	1.14	+0.16
Calmar ratio Return relative to maximum drawdown	2.25	0.48	+1.77
Martin ratio Return relative to average drawdown	4.23	0.77	+3.46
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CHCI vs. BCRX - Sharpe Ratio Comparison

The current CHCI Sharpe Ratio is 1.72, which is higher than the BCRX Sharpe Ratio of 0.53. The chart below compares the historical Sharpe Ratios of CHCI and BCRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CHCI	BCRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.72	0.53	+1.18
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.43	-0.01	+0.45
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.29	0.18	+0.11
Sharpe Ratio (All Time) Calculated using the full available price history	-0.06	0.01	-0.08

Correlation

The correlation between CHCI and BCRX is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CHCI vs. BCRX - Dividend Comparison

Neither CHCI nor BCRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CHCI vs. BCRX - Drawdown Comparison

The maximum CHCI drawdown since its inception was -99.80%, roughly equal to the maximum BCRX drawdown of -97.74%. Use the drawdown chart below to compare losses from any high point for CHCI and BCRX.

Drawdown Indicators

	CHCI	BCRX	Difference
Max Drawdown Largest peak-to-trough decline	-99.80%	-97.74%	-2.06%
Max Drawdown (1Y) Largest decline over 1 year	-44.23%	-44.24%	+0.01%
Max Drawdown (5Y) Largest decline over 5 years	-51.18%	-79.10%	+27.92%
Max Drawdown (10Y) Largest decline over 10 years	-75.34%	-83.69%	+8.35%
Current Drawdown Current decline from peak	-90.89%	-71.26%	-19.63%
Average Drawdown Average peak-to-trough decline	-92.10%	-69.63%	-22.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.56%	27.45%	-3.89%

Volatility

CHCI vs. BCRX - Volatility Comparison

Comstock Holding Companies, Inc. (CHCI) has a higher volatility of 24.22% compared to BioCryst Pharmaceuticals, Inc. (BCRX) at 15.92%. This indicates that CHCI's price experiences larger fluctuations and is considered to be riskier than BCRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CHCI	BCRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	24.22%	15.92%	+8.30%
Volatility (6M) Calculated over the trailing 6-month period	46.18%	34.22%	+11.96%
Volatility (1Y) Calculated over the trailing 1-year period	70.73%	50.81%	+19.92%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	62.62%	63.41%	-0.79%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	93.08%	72.94%	+20.14%

Financials

CHCI vs. BCRX - Profitability Comparison

The chart below illustrates the profitability comparison between Comstock Holding Companies, Inc. and BioCryst Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CHCI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Comstock Holding Companies, Inc. reported a gross profit of 1.46M and revenue of 13.32M. Therefore, the gross margin over that period was 11.0%.

BCRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, BioCryst Pharmaceuticals, Inc. reported a gross profit of 397.03M and revenue of 406.56M. Therefore, the gross margin over that period was 97.7%.

CHCI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Comstock Holding Companies, Inc. reported an operating income of 661.00K and revenue of 13.32M, resulting in an operating margin of 5.0%.

BCRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, BioCryst Pharmaceuticals, Inc. reported an operating income of 260.39M and revenue of 406.56M, resulting in an operating margin of 64.1%.

CHCI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Comstock Holding Companies, Inc. reported a net income of 541.00K and revenue of 13.32M, resulting in a net margin of 4.1%.

BCRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, BioCryst Pharmaceuticals, Inc. reported a net income of 245.85M and revenue of 406.56M, resulting in a net margin of 60.5%.